2008
DOI: 10.1007/s00277-008-0583-8
|View full text |Cite
|
Sign up to set email alerts
|

A limited number of 5-azacitidine cycles can be effective treatment in MDS

Abstract: International audienceHypomethylating agents, such as 5-azacitidine (5-AZA) and 5-aza-2'-deoxycytidine (decitabine), have recently been approved for the treatment of myelodysplastic syndromes (MDS). Several randomized trials have shown favorable results concerning response rate, survival, transformation to acute leukemia, and quality of life. In these trials, treatment was administered continuously until progression. In the retrospective study presented here, we evaluated the outcome of patients with higher ri… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

1
14
0

Year Published

2009
2009
2012
2012

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 28 publications
(15 citation statements)
references
References 23 publications
1
14
0
Order By: Relevance
“…administration is also possible, the majority of patients receive the drug s.c., according to the phase III trial that was the basis for approval in the European Union. The drug appears to be very well tolerated, however, and in agreements with a recent report in this journal [4], local injection site skin reactions are observed within the most common nonhematological adverse events. This side effect, although usually completely and spontaneously reversible, often is of inflammatory nature and can be painful, displaying therefore a challenge in the daily clinical care of these patients.…”
supporting
confidence: 50%
“…administration is also possible, the majority of patients receive the drug s.c., according to the phase III trial that was the basis for approval in the European Union. The drug appears to be very well tolerated, however, and in agreements with a recent report in this journal [4], local injection site skin reactions are observed within the most common nonhematological adverse events. This side effect, although usually completely and spontaneously reversible, often is of inflammatory nature and can be painful, displaying therefore a challenge in the daily clinical care of these patients.…”
supporting
confidence: 50%
“…Sixteen of the identified trials were excluded for various reasons (Figure 1). 5,8,[14][15][16][17][18][19][20][21][22][23][24][25][26][27] Of the five publications considered relevant for the meta-analysis, two reported different outcomes on the same trial, of which only one was relevant. Thus, four trials including 952 patients and performed between the years 2002 and 2008 fulfilled the inclusion criteria (Table 1).…”
Section: Resultsmentioning
confidence: 99%
“…In a small retrospective study, the outcome of patients with higher-risk MDS treated with a limited number of azacitidine cycles was analyzed. 68 Patients were treated for a median of 4 cycles, with only 2 additional cycles administered as consolidation if a response was achieved after 4 cycles. Although patients clearly benefited even from this limited number of treatment courses, remission rates were lower and median survival was inferior to the AZA-001 trial where treatment was continued until progression.…”
Section: Dosing Of Azacitidine and Duration Of Therapymentioning
confidence: 99%